Prime Medicine Inc (NASDAQ:PRME)’s traded shares stood at 1.95 million during the last session, with the company’s beta value hitting 2.04. At the close of trading, the stock’s price was $2.00, to imply an increase of 13.64% or $0.24 in intraday trading. The PRME share’s 52-week high remains $8.27, putting it -313.5% down since that peak but still an impressive 17.5% since price per share fell to its 52-week low of $1.65. The company has a valuation of $262.32M, with an average of 1.6 million shares in intraday trading volume over the past 10 days and average of 1.12 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Prime Medicine Inc (PRME), translating to a mean rating of 1.17. Of 5 analyst(s) looking at the stock, 0 analyst(s) give PRME a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 4 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.31.
Prime Medicine Inc (NASDAQ:PRME) trade information
After registering a 13.64% upside in the last session, Prime Medicine Inc (PRME) has traded red over the past five days. The 5-day price performance for the stock is 4.71%, and -33.11% over 30 days. With these gigs, the year-to-date price performance is -31.51%. Short interest in Prime Medicine Inc (NASDAQ:PRME) saw shorts transact 18.04 million shares and set a 17.29 days time to cover.
The extremes give us $12 and $23 for target low and target high price respectively. As such, PRME has been trading -1050.0% off suggested target high and -500.0% from its likely low.
Prime Medicine Inc (PRME) estimates and forecasts
The rating firms project that company’s revenue will grow 560.21% compared to the previous financial year. Revenue forecast for the current quarter as set by 9 analysts is 3.43M. Meanwhile, for the current quarter, a total of 9 analyst(s) estimate revenue growth to 3.39M.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -124.13% for the past 5-year period. While 2025 is set for a 27.26% return in earnings, projections for the next 5 years are at 12.59% annually.
PRME Dividends
Prime Medicine Inc has its next earnings report out on 2025-Feb-27. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Prime Medicine Inc (NASDAQ:PRME)’s Major holders
Prime Medicine Inc insiders hold 23.91% of total outstanding shares, with institutional holders owning 59.05% of the shares at 77.60% float percentage. In total, 59.05% institutions holds shares in the company, led by ALPHABET INC. As of 2024-06-30, the company held over 15.06 million shares (or 12.6375% of shares), all amounting to roughly $77.42 million.
The next major institution holding the largest number of shares is ARK INVESTMENT MANAGEMENT LLC with 6.13 million shares, or about 5.1404% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $31.49 million.
We also have ARK Genomic Revolution ETF and ARK Innovation ETF as the top two Mutual Funds with the largest holdings of the Prime Medicine Inc (PRME) shares. Going by data provided on Feb 28, 2025, ARK Genomic Revolution ETF holds roughly 2.59 shares. This is just over 1.98% of the total shares, with a market valuation of $5.18 million. Data from the same date shows that the other fund manager holds a little less at 2.17, or 1.66% of the shares, all valued at about 4.35 million.
